PREOPERATIVE INTRAPERITONEAL CHEMOTHERAPY FOR GASTRIC-CANCER, WITH SPECIAL REFERENCE TO DELAYED PERITONEAL COMPLICATIONS

被引：12

作者：

ADACHI, W

KOIKE, S

RAFIQUE, M

KAJIKAWA, S

KANEKO, G

KURODA, T

IIDA, F

ISHII, K

机构：

[1] Department of Surgery, Shinshu University School of Medicine, Nagano, 390, 3-1-1 Asahi, Matsumoto

[2] Central Clinical Laboratories, Shinshu University School of Medicine, Nagano, 390, 3-1-1 Asahi, Matsumoto

来源：

SURGERY TODAY-THE JAPANESE JOURNAL OF SURGERY | 1995年 / 25卷 / 05期

关键词：

GASTRIC CANCER; INTRAPERITONEAL CHEMOTHERAPY; INTESTINAL OBSTRUCTION; PERITONITIS; ADHESION;

D O I：

10.1007/BF00311815

中图分类号：

R61 [外科手术学];

学科分类号：

摘要：

Preoperative intraperitoneal (IP) chemotherapy was performed in 23 patients with gastric malignancies to inhibit peritoneal recurrence. Cis-diamminedichloroplatinum (CDDP) and mitomycin C (MMC) were administered intraperitoneally 3 days prior to surgery, at which time a very viscid peritoneum and mucinous intraperitoneal fluid were found in 100% and 83% of the patients, respectively. Inflammatory changes were microscopically observed in the subserosal layer of the resected stomachs and in the intraperitoneal fluid, but degenerative changes characteristic of cancer cells could not be seen. The 3-year survival rate of the stage III patients was 55.6%, and peritoneal recurrence was found in three of six patients with recurrence. Extensive adhesions were found in eight patients (34.8%) as a delayed peritoneal complication, and chronic bowel obstruction resulting from the adhesion developed in five patients (21.7%). Thus, we conclude that the administration of this IP chemotherapy demonstrated no definite antitumor effects or survival benefits, but was frequently associated with delayed peritoneal complications.

引用

页码：396 / 403

页数：8

共 29 条

[1]

Dedrick R.L., Myers C.E., Bungay P.M., DeVita V.T., Cancer Treat Rep, 62, pp. 1-11, (1978)

[2]

Howell S.B., Pfeifle C.L., Wung W.E., Olshen R.A., Lucas W.E., Yon J.L., Green M., Intraperitoneal cisplatin with systemic thiosulfate protection, Ann Int Med, 97, pp. 845-851, (1982)

[3]

Zylberberg B., Ravina J.H., Salat-Baroux J., Madelenat P., Zarca D., Dormont D., Chemotherapy by the intravenous and intraperitoneal routes combined in ovarian cancer, Gynecologic Oncology, 36, pp. 271-276, (1990)

[4]

Markman M., Intracavitary chemotherapy for malignant disease confined to body cavities, West J Med, 142, pp. 364-368, (1985)

[5]

Sugarbaker P.H., Gianola F.J., Speyer J.C., Wesley R., Barofsky I., Meyers C.E., Prospective, randomized trial of intravenous versus intraperitoneal 5-fluorouracil in patients with advanced primary colon or rectal cancer, Surgery, 98, pp. 414-422, (1985)

[6]

Hagiwara A., Takahashi T., Kojima O., Sawai K., Yamaguchi T., Yamane T., Taniguchi H., Kitamura K., Noguchi A., Seiki K., Sakakura C., Prophylaxis with carbon-adsorbed mitomycin against peritoneal recurrence of gastric cancer, Lancet, 339, pp. 629-631, (1992)

[7]

Iwanaga T., Koyama H., Furukawa H., Taniguchi H., Wada A., Tateishi R., Mechanisms of late recurrence after radical surgery for gastric carcinoma, Am J Surg, 135, pp. 637-640, (1978)

[8]

Fujimoto S., Shrestha R.D., Kokubun M., Ohta M., Takahashi M., Kobayashi K., Kiuchi S., Okui K., Miyoshi T., Arimizu N., Takamizawa H., Intraperitoneal hyperthermic perfusion combined with surgery effective for gastric cancer patients with peritoneal seeding, Ann Surg, 208, pp. 36-41, (1988)

[9]

Fujimura T., Yonemura Y., Fushida S., Urade M., Takegawa S., Kamata T., Sugiyama K., Hasegawa H., Katayama K., Miwa K., Miyazaki I., Continuous hyperthermic peritoneal perfusion for the treatment of peritoneal dissemination in gastric cancers and subsequent second-look operation, Cancer, 65, pp. 65-71, (1990)

[10]

The general rules for the gastric cancer study in surgery and pathlogy. Part I. Clinical classification, Jpn J Surg, 11, pp. 127-139, (1981)

← 1 2 3 →